Compounding Pharmacies: Registration Is Not Capability

Compounding pharmacies are bought by health systems as a cost-avoidance service and evaluated as a regulatory risk. The two views produce different supplier shortlists, and the gap between them is where outsourcing decisions go wrong.

This note is for hospital procurement leads and pharmacy directors evaluating 503B-style outsourcing facilities or regional compounding partners. It covers what the registration status actually guarantees, how to read an environmental monitoring report, and the acceptance checks that belong in the service agreement rather than in the audit report.

The market structure behind the category, including the split between hospital-based and outsourced compounding, is covered in this analysis of the compounding pharmacies market.

Registration status tells you which category a facility sits in, not what it can actually make

Outsourcing facility registration establishes which regulatory framework applies and what inspection frequency follows from it. It does not tell you whether the facility can make your formulation reproducibly, and it does not tell you whether its deviation history is clean.

Ask for the inspection outcome and the form of any observations, not merely the registration number. A facility with open observations in environmental monitoring is a different supplier from one with a clean record, even though both hold the same registration.

Environmental monitoring data is the most diagnostic document you will receive

An environmental monitoring programme samples surfaces and air in the controlled areas and reports colony-forming units against defined limits. The value is not in a single passing report but in the trend: excursions that cluster in one room, or in one season, point to a facility problem rather than to a sampling artefact.

Ask for twelve months of data with the sampling locations identified. A supplier who provides a summary certificate rather than the underlying results is controlling the narrative, and the buyer cannot perform the trend analysis that matters.

Beyond-use dating is a claim that needs a basis

Beyond-use dating for a compounded preparation is set from stability data and from microbiological risk, and the two are often conflated in commercial discussions. A long date assigned on the basis of chemical stability alone ignores the microbiological question that dominates for multi-dose preparations.

Ask which basis applies to each product line and whether the date assumes storage at the labelled condition throughout. Cold-chain excursions in transit invalidate a date that was established for controlled storage, and the responsibility for detecting an excursion sits with whoever owns the shipping lane.

Capacity and turnaround are part of clinical risk

A supplier that cannot deliver on the promised day creates a clinical problem that no quality system compensates for. Ask for on-time delivery performance over the past year, by product line, and ask how the facility handles a stat request that arrives outside its production schedule.

Then check the answer against your own formulary. A facility that is excellent at routine batch production and poor at patient-specific preparation is a poor fit for a hospital that needs both, and the mismatch is visible in the deviation log long before it becomes a clinical incident.

What the service agreement must contain

Require notification of any inspection observation within a defined period, notification of any recall or market withdrawal, and the right to audit with reasonable notice. Require the deviation handling procedure and the definition of a critical deviation.

Then require the exit terms: how records are transferred, how work in progress is handled, and what happens to stability data that the buyer paid for. Compounding relationships end, and the exit clause is the part nobody reads until it matters.

Consumables and container closure deserve their own review

The quality of a compounded preparation depends on the vial, the closure and the transfer devices as much as on the facility. A sterile filter that was validated on one product family may behave differently on another, and a closure system qualified for one stopper may not be qualified for a substitute.

Buyers who want to understand how these consumables are sourced and qualified can read the structure of the disposable and implantable consumables supply base, which follows the same qualification logic from component to finished pack.

Cost comparison that includes the hidden line items

The headline saving against in-house preparation usually excludes the labour of managing the relationship, the cost of the audit programme, the inventory carried to cover delivery variability, and the write-off when a batch is short-dated on arrival.

Build a total cost model with those four lines before signing. The result frequently narrows the apparent saving to the point where the decision turns on capability rather than price, which is the more honest basis for choosing a partner.

Sterility assurance is an argument, not a test

Sterility cannot be demonstrated by testing a finished unit, so the assurance comes from the process and from the validation behind it. Ask how the facility validates its aseptic process, what media fill frequency it runs, and what its investigation looked like the last time a fill failed.

A facility that describes validation as complete rather than continuous is describing a document, not a control strategy. The answer to the media fill question tells you which one you are dealing with.

Run a recall drill before you sign

Ask the supplier to walk through a recall scenario with your product in it: who calls whom, in what order, within what time, and how the affected lot is identified in their system. The answer is the clearest evidence of whether the quality system is operational.

Do this before signing, and write the timeline into the agreement. A recall that takes four days to reach a ward is a clinical event, not an administrative one.

Measure the relationship with three numbers

On-time delivery, deviation rate per batch and complaint closure time. Three numbers, reviewed quarterly, will tell you more about a compounding partner than an annual audit report, because they track behaviour rather than capability claims.

Agree the definitions before the first review. A deviation rate that counts only critical deviations is a different metric from one that counts all of them, and the difference is where supplier reporting becomes marketing.

Always hold a second source, even at higher cost

A single compounding partner is a single point of clinical failure, and the cost of a second qualification is small against the cost of a supply interruption in a therapeutic category with no substitute.

Qualify the second source on your highest-risk formulation, not on the easiest one. The exercise is about proving the pathway works under pressure.

FAQ: questions buyers ask

Is a registered facility automatically safer?

It is subject to a defined inspection regime, which is not the same as being safer. The inspection record and the deviation history carry more information than the registration itself.

How often should we audit?

Annually at minimum, and sooner after any critical deviation or inspection observation. The audit should follow the trend data, not a fixed checklist.

Can we rely on the supplier's stability data?

Only if you know the storage assumptions and the analytical methods. Ask for the protocol, not the conclusion.

What is the first question to ask a new supplier?

What was your last inspection outcome and what observations remain open. The answer sets the tone for everything that follows.

Where do most quality failures originate?

In the interface between the facility and the buyer: transport conditions, container closure substitution and unclear specifications. All three are controllable in the agreement.

The discipline is unglamorous but decisive: read the trend rather than the certificate, and write the acceptance criteria into the contract while you still have leverage. Buyers who do that once tend to keep the same template for every clinical outsource decision that follows, which is where the compounding saving actually becomes predictable rather than assumed at the outset of the relationship.